Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01313039 · ClinicalTrials.gov registry record · Early Phase 1
Evaluation of the Use of AZD6244 to Induce Increased ER Expression and Anti-Estrogen Response in ER-Negative/Low Breast Cancer
A Early Phase 1 study, sponsored by University of Miami.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 4
- Enrollment target
NCT01313039 is a Early Phase 1 study that has completed, run by University of Miami. The registered enrollment target is 4 participants.
The verdict
NCT01313039, a Early Phase 1 study, has completed, sponsored by University of Miami.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
If AZD6244 is able to increase ER expression in ER-negative/low cancers then it may be possible to effectively use hormonal therapy in these patients resulting in improved outcomes. The investigators propose a single-arm Simon two-step study to examine whether treatment with AZD6244 will result in increased ER expression in ER-negative/low primary breast tumors.
Interventions
- DRUG AZ6244
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2011-02 |
| Est. Completion | 2014-04 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01313039
The ClinicalTrials.gov registry entry for NCT01313039 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Miami, which has 721 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AZ6244 is the first listed.
NCT01313039 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01313039 about?
NCT01313039 is a clinical study titled "Evaluation of the Use of AZD6244 to Induce Increased ER Expression and Anti-Estrogen Response in ER-Negative/Low Breast Cancer". If AZD6244 is able to increase ER expression in ER-negative/low cancers then it may be possible to effectively use hormonal therapy in these patients resulting in improved outcomes. The investigators propose a single-arm Simon two-step study to examine whether treatment with AZD6244 will result in i...
What is the current status of trial NCT01313039?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 4 participants. The study started on 2011-02. Estimated completion is 2014-04.
What interventions are being tested in trial NCT01313039?
The interventions under investigation include: AZ6244 (DRUG).
Who is sponsoring clinical trial NCT01313039?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.